Company news
Halozyme Therapeutics, Inc. news in 2025
Halozyme Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Huonslab Announces Submission of Biologics License Application for Recombinant Human Hyaluronidase ‘HYDIZYME™’
December 22, 2025
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer
December 17, 2025
Bench International Announces Appointment of Jim Lang to the Board of Directors of Halozyme Therapeutics
December 17, 2025
Jim Lang Elected to Halozyme's Board of Directors
December 7, 2025
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
December 3, 2025
Halozyme to Participate in the 8th Annual Evercore Healthcare Conference
November 24, 2025
Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery
November 17, 2025
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab
November 16, 2025
FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma
November 7, 2025
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032
November 5, 2025
Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032
November 4, 2025
Halozyme raises 2025 financial guidance and reports strong third quarter 2025 financial and operating results
November 2, 2025
Halozyme to Report Third Quarter 2025 Financial and Operating Results
October 20, 2025
Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s
September 30, 2025
Halozyme to Participate at Upcoming Investor Conferences
August 27, 2025
Halozyme raises 2025 financial guidance ranges and reports strong second quarter 2025 results
August 4, 2025
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma
July 23, 2025
Halozyme to Report Second Quarter 2025 Financial and Operating Results
July 21, 2025
Halozyme Therapeutics Added to Russell 1000® Index
June 29, 2025
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
June 19, 2025
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications
May 27, 2025
Halozyme raises 2025 financial guidance ranges and reports strong first quarter 2025 results
May 5, 2025
Halozyme to Participate in the BofA Securities 2025 Healthcare Conference
May 4, 2025
Halozyme to Report First Quarter 2025 Financial and Operating Results
April 27, 2025
Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
April 27, 2025
Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation
April 23, 2025
Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
April 9, 2025
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility
April 8, 2025
European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
April 6, 2025
Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications
March 30, 2025
Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference
February 25, 2025
Halozyme reports full year 2024 record revenue of $1.015 billion and exceeds its financial guidance for royalty revenue, adjusted EBITDA and non-GAAP diluted EPS
February 17, 2025
Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results
February 3, 2025
CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
February 2, 2025
Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance
January 7, 2025
Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance
January 5, 2025
Calls in 2025
- Halozyme Therapeutics (NASDAQ:HALO) Q3 2025 Earnings Call
Nov 3, 2025
Transcript - Halozyme Therapeutics (NASDAQ:HALO) Q2 2025 Earnings Call
Aug 5, 2025
Transcript - Halozyme Therapeutics (NASDAQ:HALO) Q1 2025 Earnings Call
May 6, 2025
Transcript - Halozyme Therapeutics (NASDAQ:HALO) Q4 2024 Earnings Call
Feb 18, 2025
Transcript
Decks in 2025
- Q3 2025 Earnings Presentation
Earnings · 22 slides · Nov 3, 2025
- Corporate Update (October 2025)
Corporate update · 12 slides · Oct 14, 2025
- Merger or Acquisition (October 2025)
Merger or acquisition · 23 slides · Oct 1, 2025
- Q2 2025 Earnings Presentation
Earnings · 19 slides · Aug 5, 2025
- Q1 2025 Earnings Presentation
Earnings · 22 slides · May 6, 2025
- Q4 2024 Earnings Presentation
Earnings · 23 slides · Feb 18, 2025
- Investor Presentation (January 2025)
Investor deck · 19 slides · Jan 8, 2025